Doxorubicin
Information
- Drug Name
- Doxorubicin
- Description
- Entry(CIViC)
- 14
CIViC
Annotation
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03533582 | Active, not recruiting | Phase 2/Phase 3 | Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery | May 24, 2018 | June 30, 2026 |
| NCT01783535 | Active, not recruiting | Phase 2 | Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma | June 19, 2013 | January 2028 |
| NCT01796197 | Active, not recruiting | Phase 2 | Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa | August 2013 | July 2024 |
| NCT03517449 | Active, not recruiting | Phase 3 | Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) | June 11, 2018 | October 7, 2024 |
| NCT01840592 | Active, not recruiting | Phase 2 | Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib | April 2013 | April 2025 |
| NCT01275677 | Active, not recruiting | Phase 3 | Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer | January 6, 2011 | July 12, 2024 |
| NCT03792867 | Active, not recruiting | N/A | Radical Resection and HIPEC for Recurrent Retroperitoneal Sarcoma | July 23, 2018 | March 31, 2024 |
| NCT04293393 | Active, not recruiting | Phase 2 | Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients | October 2, 2020 | February 28, 2033 |
| NCT03467373 | Active, not recruiting | Phase 1 | A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL | March 13, 2018 | October 30, 2024 |
| NCT04980222 | Active, not recruiting | Phase 2 | A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma | March 22, 2022 | June 1, 2025 |
| NCT03407144 | Active, not recruiting | Phase 2 | Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) | April 9, 2018 | February 13, 2027 |
| NCT01857934 | Active, not recruiting | Phase 2 | Therapy for Children With Advanced Stage Neuroblastoma | July 5, 2013 | December 2024 |
| NCT03036488 | Active, not recruiting | Phase 3 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) | March 7, 2017 | September 30, 2025 |
| NCT03792256 | Active, not recruiting | Phase 1 | Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) | April 11, 2019 | June 30, 2025 |
| NCT01864109 | Active, not recruiting | Phase 2 | Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma | May 2013 | May 2027 |
| NCT01871766 | Active, not recruiting | Phase 2 | Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy | December 4, 2013 | June 2030 |
| NCT04055753 | Active, not recruiting | Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma | August 12, 2016 | May 2024 | |
| NCT04824092 | Active, not recruiting | Phase 3 | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients | May 11, 2021 | May 2026 |
| NCT04569032 | Active, not recruiting | Phase 2 | A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression | November 12, 2020 | September 30, 2024 |
| NCT03020030 | Active, not recruiting | Phase 3 | Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents | March 3, 2017 | November 2034 |
| NCT01920932 | Active, not recruiting | Phase 2 | Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma | August 12, 2013 | May 2028 |
| NCT03017326 | Active, not recruiting | Phase 3 | Paediatric Hepatic International Tumour Trial | August 24, 2017 | August 1, 2027 |
| NCT03786783 | Active, not recruiting | Phase 2 | Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma | March 4, 2019 | September 22, 2024 |
| NCT01946529 | Active, not recruiting | Phase 2 | Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors | December 27, 2013 | July 2026 |
| NCT01358877 | Active, not recruiting | Phase 3 | A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer | November 8, 2011 | November 28, 2024 |
| NCT05113251 | Active, not recruiting | Phase 3 | Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer | October 25, 2021 | April 30, 2027 |
| NCT05448820 | Active, not recruiting | Phase 1/Phase 2 | YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma | November 14, 2022 | September 2025 |
| NCT04032964 | Active, not recruiting | Phase 1 | Dose Finding Study of L19TNF and Doxorubicin in Patients With STS | September 5, 2019 | December 2024 |
| NCT00476190 | Active, not recruiting | Phase 2 | ALL Adult Consortium Trial: Adult ALL Trial | April 2007 | December 2024 |
| NCT05201248 | Active, not recruiting | Phase 1 | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma | March 10, 2022 | December 13, 2024 |
| NCT01424982 | Active, not recruiting | Phase 2 | Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia | October 5, 2011 | October 31, 2025 |
| NCT00479128 | Active, not recruiting | Phase 1 | Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors | September 28, 2006 | September 30, 2024 |
| NCT04914741 | Active, not recruiting | Phase 1/Phase 2 | A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) | June 29, 2021 | July 2025 |
| NCT00136435 | Active, not recruiting | Phase 2 | A Study in Adults With Untreated Acute Lymphoblastic Leukemia | June 2002 | July 2024 |
| NCT01464606 | Active, not recruiting | N/A | International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry | December 22, 2009 | December 2024 |
| NCT00092222 | Active, not recruiting | Phase 2 | Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity | October 28, 2004 | October 1, 2025 |
| NCT03719430 | Active, not recruiting | Phase 2 | APX005M and Doxorubicin in Advanced Sarcoma | March 20, 2019 | December 31, 2025 |
| NCT02112916 | Active, not recruiting | Phase 3 | Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma | October 4, 2014 | September 22, 2024 |
| NCT03712202 | Active, not recruiting | Phase 2 | Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma | November 28, 2018 | September 23, 2024 |
| NCT04529772 | Active, not recruiting | Phase 3 | A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | October 8, 2020 | February 5, 2027 |
| NCT04024462 | Active, not recruiting | Phase 3 | A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer | February 5, 2020 | November 11, 2025 |
| NCT02180867 | Active, not recruiting | Phase 2/Phase 3 | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | July 11, 2014 | December 22, 2024 |
| NCT04517435 | Active, not recruiting | Phase 1/Phase 2 | ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma | April 28, 2021 | July 2025 |
| NCT02979522 | Active, not recruiting | Phase 1/Phase 2 | A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma | September 6, 2017 | September 24, 2029 |
| NCT04083963 | Active, not recruiting | Phase 2 | Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer | August 9, 2019 | September 27, 2026 |
| NCT03274492 | Active, not recruiting | Phase 3 | A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma | November 16, 2017 | June 27, 2024 |
| NCT05498896 | Active, not recruiting | Phase 2 | Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC | December 19, 2018 | January 30, 2026 |
| NCT02957968 | Active, not recruiting | Phase 2 | Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca | January 24, 2017 | February 28, 2025 |
| NCT02911142 | Active, not recruiting | Phase 1/Phase 2 | Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma | July 3, 2017 | October 1, 2027 |
| NCT03646123 | Active, not recruiting | Phase 2 | Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma | January 28, 2019 | June 7, 2026 |
| NCT05275777 | Active, not recruiting | Phase 1/Phase 2 | A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer | May 19, 2022 | February 2030 |
| NCT02306161 | Active, not recruiting | Phase 3 | Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma | December 12, 2014 | September 22, 2024 |
| NCT03817320 | Active, not recruiting | Phase 1/Phase 2 | PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma | February 12, 2019 | June 30, 2025 |
| NCT03595592 | Active, not recruiting | Phase 3 | Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer | September 7, 2018 | March 15, 2027 |
| NCT02889523 | Active, not recruiting | Phase 1/Phase 2 | Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy | October 2016 | April 2026 |
| NCT02876302 | Active, not recruiting | Phase 2 | Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer | January 24, 2018 | August 2024 |
| NCT03233347 | Active, not recruiting | Phase 2 | Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma | October 13, 2017 | July 8, 2025 |
| NCT02451943 | Active, not recruiting | Phase 3 | A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma | September 14, 2015 | July 31, 2024 |
| NCT03159897 | Active, not recruiting | Phase 3 | FIL Study on ABVD DD-DI as Upfront Therapy in HL. | August 1, 2017 | May 2024 |
| NCT03587662 | Active, not recruiting | Phase 2 | Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | August 17, 2018 | January 31, 2025 |
| NCT03117751 | Active, not recruiting | Phase 2/Phase 3 | Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | March 29, 2017 | March 31, 2028 |
| NCT00006721 | Active, not recruiting | Phase 3 | S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma | March 2001 | March 2024 |
| NCT01712490 | Active, not recruiting | Phase 3 | A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma | November 9, 2012 | January 13, 2026 |
| NCT03113500 | Active, not recruiting | Phase 2 | Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma | May 25, 2017 | December 21, 2024 |
| NCT03101748 | Active, not recruiting | Phase 1/Phase 2 | Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer | January 29, 2018 | January 1, 2026 |
| NCT02419495 | Active, not recruiting | Phase 1 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | June 26, 2015 | December 31, 2024 |
| NCT01746238 | Active, not recruiting | Phase 1 | Bevacizumab/Doxorubicin/Radiation for Sarcoma | March 2013 | January 2025 |
| NCT02734771 | Active, not recruiting | Phase 2 | A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) | June 2016 | June 2024 |
| NCT02723994 | Active, not recruiting | Phase 2 | A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia | September 30, 2016 | February 1, 2026 |
| NCT02427620 | Active, not recruiting | Phase 2 | Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma | June 3, 2015 | June 30, 2025 |
| NCT02710734 | Active, not recruiting | Phase 2 | Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN) | February 24, 2016 | February 2034 |
| NCT05218499 | Active, not recruiting | Phase 2/Phase 3 | Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma | March 25, 2022 | May 27, 2026 |
| NCT00878254 | Active, not recruiting | Phase 2 | Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma | March 25, 2009 | September 2027 |
| NCT05008224 | Active, not recruiting | Phase 2 | Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11) | October 7, 2021 | May 22, 2024 |
| NCT02661503 | Active, not recruiting | Phase 3 | HD21 for Advanced Stages | July 2016 | September 2025 |
| NCT00471965 | Completed | Phase 3 | Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients | March 2007 | March 2010 |
| NCT00477412 | Completed | Phase 1/Phase 2 | Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma | April 3, 2007 | October 28, 2020 |
| NCT00483509 | Completed | Phase 2 | Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma | February 14, 2007 | May 17, 2011 |
| NCT00484341 | Completed | Phase 2 | Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas. | October 2010 | May 2016 |
| NCT00484432 | Completed | Phase 2 | Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer | November 2008 | June 2016 |
| NCT00493870 | Completed | Phase 3 | TAC Versus TC for Adjuvant Breast Cancer | May 29, 2007 | March 30, 2020 |
| NCT00494780 | Completed | Phase 2 | Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients | June 2007 | September 2010 |
| NCT00499122 | Completed | Phase 2 | NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer | June 4, 2007 | April 2011 |
| NCT00502411 | Completed | Phase 1 | Post-Operative Chemoradiation for Extremity & Trunk Soft Tissue Sarcoma | January 2003 | April 2015 |
| NCT00506155 | Completed | Phase 2 | Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer | June 2007 | August 2014 |
| NCT00510367 | Completed | Early Phase 1 | Primary Breast Cancer Occurring Concomitant With Pregnancy | August 7, 2001 | July 8, 2020 |
| NCT00530101 | Completed | Phase 1 | The Magnetic Resonance Imaging Evaluation of Doxorubicin Cardiotoxicity | July 2004 | March 2008 |
| NCT00536393 | Completed | Phase 2/Phase 3 | Treatment of Disseminated High Grade Lymphoma | October 2000 | October 2004 |
| NCT00544167 | Completed | N/A | Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer | May 2007 | April 2011 |
| NCT00546156 | Completed | Phase 2 | Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer | October 2007 | December 2012 |
| NCT00574587 | Completed | Phase 1/Phase 2 | Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy | December 2007 | May 2014 |
| NCT00575406 | Completed | Phase 2 | Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma | December 2007 | January 2012 |
| NCT00577629 | Completed | Phase 2 | Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma | June 18, 2005 | November 3, 2016 |
| NCT00577993 | Completed | Phase 3 | Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients | March 16, 1998 | August 24, 2017 |
| NCT00578864 | Completed | Phase 2 | Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma | March 2007 | March 2015 |
| NCT00580333 | Completed | Phase 2 | Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer | September 2007 | June 2020 |
| NCT00581776 | Completed | Phase 2 | Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma | May 2005 | May 2015 |
| NCT00586846 | Completed | Phase 2 | Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed Osteosarcoma | July 2003 | February 2009 |
| NCT00590785 | Completed | Phase 3 | Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394) | August 13, 1996 | January 13, 2015 |
| NCT00613457 | Completed | Phase 3 | Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia | September 2000 | July 2006 |
| NCT00626704 | Completed | Phase 1/Phase 2 | Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma | November 2007 | March 2011 |
| NCT00634179 | Completed | Phase 1/Phase 2 | A Phase I/II Trial of VR-CHOP in Lymphoma Patients | February 2008 | November 2015 |
| NCT04081389 | Completed | Phase 1 | Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer | December 6, 2019 | February 27, 2023 |
| NCT00651755 | Completed | N/A | Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients | March 2008 | September 2011 |
| NCT00667342 | Completed | Phase 2 | A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma | June 3, 2008 | August 2017 |
| NCT00669877 | Completed | Phase 2 | Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma | August 2002 | October 2015 |
| NCT00671658 | Completed | Phase 2 | Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia | November 2002 | July 2013 |
| NCT00688740 | Completed | Phase 3 | Docetaxel in Node Positive Adjuvant Breast Cancer | June 1997 | January 2010 |
| NCT00715208 | Completed | Phase 2 | Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma | September 2008 | March 2011 |
| NCT04047004 | Completed | Phase 1 | Adjuvant PIPAC in Gastric Cancer Patients | March 11, 2020 | October 1, 2022 |
| NCT00722293 | Completed | Phase 1 | A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors | July 8, 2008 | February 25, 2014 |
| NCT00770224 | Completed | Phase 2 | S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma | April 2009 | August 2019 |
| NCT00787527 | Completed | Phase 1/Phase 2 | SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma | November 2008 | December 2012 |
| NCT00789581 | Completed | Phase 3 | A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer | December 2008 | November 2016 |
| NCT00796120 | Completed | Phase 3 | An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS) | November 2008 | August 2014 |
| NCT00798252 | Completed | Phase 1 | Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers | March 2009 | May 2015 |
| NCT00801281 | Completed | Phase 3 | First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. | February 2007 | June 25, 2017 |
| NCT00808639 | Completed | Phase 2 | Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma | December 2008 | September 2016 |
| NCT03991884 | Completed | Phase 1 | Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia | September 24, 2019 | June 28, 2023 |
| NCT00814541 | Completed | Phase 2 | PAD. ICORG 05-01, V11 | December 2005 | December 2012 |
| NCT03817853 | Completed | Phase 4 | An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma | February 26, 2019 | January 25, 2023 |
| NCT00825149 | Completed | Phase 1 | A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma | February 2009 | November 2015 |
| NCT03804866 | Completed | Phase 2 | NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018) | March 2013 | December 2016 |
| NCT00866749 | Completed | Phase 2 | Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma | September 12, 2006 | July 26, 2018 |
| NCT00877006 | Completed | Phase 3 | Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study | April 30, 2009 | March 31, 2012 |
| NCT00878800 | Completed | Phase 1/Phase 2 | A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas | December 2006 | October 2012 |
| NCT00887536 | Completed | Phase 3 | A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer | May 2009 | February 2018 |
| NCT00890656 | Completed | Phase 2 | Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage | June 2003 | January 2011 |
| NCT00931918 | Completed | Phase 2 | Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients | October 2009 | August 2015 |
| NCT00944047 | Completed | Phase 2 | Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression | July 2009 | August 2017 |
| NCT00956930 | Completed | Phase 2 | Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery | August 2009 | July 15, 2016 |
| NCT00968253 | Completed | Phase 1/Phase 2 | RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia | November 2009 | December 2015 |
| NCT00969462 | Completed | Phase 4 | Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma | September 2009 | December 2012 |
| NCT00973752 | Completed | Phase 2 | Treatment of Older Adults With Acute Lymphoblastic Leukemia | August 2009 | April 2016 |
| NCT00976131 | Completed | Phase 1 | Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer | September 2009 | January 20, 2021 |
| NCT00988195 | Completed | Phase 1 | Study of Pegylated Human Recombinant Arginase for Liver Cancer | May 2008 | August 2009 |
| NCT03726879 | Completed | Phase 3 | A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer | January 11, 2019 | August 24, 2023 |
| NCT01000285 | Completed | Phase 1/Phase 2 | EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma | September 2010 | April 2016 |
| NCT01004991 | Completed | Phase 1/Phase 2 | Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma | January 2010 | February 2016 |
| NCT01008150 | Completed | Phase 2 | Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer | October 2010 | November 25, 2016 |
| NCT01027910 | Completed | Phase 1/Phase 2 | PCI-24781 in Combination With Doxorubicin to Treat Sarcoma | February 2009 | March 2015 |
| NCT01040871 | Completed | Phase 2 | Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma | January 2010 | August 2012 |
| NCT01060904 | Completed | Phase 1 | A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | January 2010 | September 2012 |
| NCT03677141 | Completed | Phase 1/Phase 2 | A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma | March 8, 2019 | October 12, 2023 |
| NCT01095926 | Completed | Phase 2 | Pharmacokinetic Study of Doxorubicin in Children With Cancer | May 2010 | May 2013 |
| NCT01148446 | Completed | Phase 3 | R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL | January 2003 | |
| NCT03604653 | Completed | Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers | May 15, 2018 | May 1, 2021 | |
| NCT01185964 | Completed | Phase 1/Phase 2 | A Study of Olaratumab in Soft Tissue Sarcoma | October 2010 | April 2016 |
| NCT01200758 | Completed | Phase 3 | A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma | February 15, 2011 | October 31, 2017 |
| NCT01205503 | Completed | Phase 2 | Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release | September 2010 | April 2015 |
| NCT03536039 | Completed | Phase 2 | RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor | January 27, 2016 | January 27, 2020 |
| NCT01251107 | Completed | Phase 3 | Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma | March 2000 | November 2009 |
| NCT03493854 | Completed | Phase 3 | A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer | June 14, 2018 | June 2, 2023 |
| NCT01309789 | Completed | Phase 1 | A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms | February 2011 | February 28, 2017 |
| NCT01319981 | Completed | Phase 2 | Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia | March 5, 2013 | November 11, 2020 |
| NCT01324180 | Completed | Phase 1 | Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL) | July 18, 2011 | July 27, 2017 |
| NCT03384654 | Completed | Phase 2 | A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | May 14, 2018 | September 27, 2022 |
| NCT01332968 | Completed | Phase 3 | A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM) | July 6, 2011 | July 30, 2021 |
| NCT02584309 | Completed | Phase 2 | Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma | February 22, 2016 | July 17, 2022 |
| NCT01358253 | Completed | Phase 4 | Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia | December 2010 | December 2012 |
| NCT01375699 | Completed | Phase 1 | Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers | August 11, 2011 | January 19, 2018 |
| NCT03349281 | Completed | Phase 1 | Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL | March 25, 2019 | October 12, 2022 |
| NCT01394354 | Completed | Phase 1/Phase 2 | Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM) | August 2011 | December 2015 |
| NCT01414855 | Completed | Phase 2 | A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER) | August 31, 2011 | December 23, 2016 |
| NCT03317457 | Completed | Phase 2 | Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma | December 15, 2017 | August 12, 2022 |
| NCT01440088 | Completed | Phase 3 | A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma | September 2011 | May 2016 |
| NCT01445535 | Completed | Phase 1 | Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas | January 13, 2009 | October 22, 2020 |
| NCT01451515 | Completed | Phase 2 | NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma | May 25, 2012 | May 31, 2022 |
| NCT03301350 | Completed | Phase 2 | Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer | November 7, 2017 | February 7, 2022 |
| NCT01481194 | Completed | Phase 2 | ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma | November 2011 | August 28, 2018 |
| NCT01490060 | Completed | N/A | Fosaprepitant in Patients Receiving Ifosfamide-based Regimen | May 2012 | March 2016 |
| NCT03283696 | Completed | Phase 1 | A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma | October 18, 2017 | August 25, 2019 |
| NCT01514188 | Completed | Phase 2 | Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma | January 11, 2012 | December 15, 2014 |
| NCT01523977 | Completed | Phase 1 | Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL | November 2011 | November 2018 |
| NCT01537029 | Completed | Phase 4 | Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide | February 2012 | December 2016 |
| NCT03248427 | Completed | Phase 2 | Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer. | July 13, 2017 | July 20, 2019 |
| NCT01569204 | Completed | Phase 2 | Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma | October 2012 | December 2017 |
| NCT01593020 | Completed | Phase 2 | Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2 | August 3, 2012 | November 4, 2020 |
| NCT01605526 | Completed | Phase 1 | A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma | May 2012 | June 2013 |
| NCT01622439 | Completed | Phase 1/Phase 2 | Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma | June 2012 | March 2018 |
| NCT03197935 | Completed | Phase 3 | A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer | July 24, 2017 | September 28, 2022 |
| NCT01678664 | Completed | Phase 2 | Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors | October 2012 | April 2019 |
| NCT01705691 | Completed | Phase 2 | Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer | September 2012 | October 2015 |
| NCT01760226 | Completed | Early Phase 1 | Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies | January 2013 | December 2016 |
| NCT01767155 | Completed | Phase 3 | Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer | April 2013 | January 30, 2017 |
| NCT01777152 | Completed | Phase 3 | ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas | January 31, 2013 | October 2, 2020 |
| NCT03056001 | Completed | Phase 2 | Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma | May 1, 2017 | November 15, 2022 |
| NCT01818063 | Completed | Phase 2 | Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer | April 25, 2013 | December 10, 2018 |
| NCT01847001 | Completed | Phase 2 | Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy | October 2012 | October 16, 2019 |
| NCT01848132 | Completed | Phase 2 | Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI. | October 3, 2013 | August 2018 |
| NCT01849783 | Completed | Phase 2 | Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma | April 4, 2013 | September 30, 2020 |
| NCT01851733 | Completed | Phase 1 | MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme | August 13, 2013 | May 30, 2018 |
| NCT01855750 | Completed | Phase 3 | A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma | September 3, 2013 | April 5, 2019 |
| NCT03042819 | Completed | Phase 1 | Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas | May 16, 2017 | June 30, 2021 |
| NCT01861951 | Completed | Phase 2 | A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma | October 2012 | July 11, 2017 |
| NCT01882816 | Completed | Phase 2 | Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer | June 13, 2013 | November 4, 2021 |
| NCT03023046 | Completed | Phase 2 | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | February 23, 2017 | May 1, 2022 |
| NCT01889069 | Completed | Phase 3 | A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) | July 31, 2013 | May 28, 2019 |
| NCT01940497 | Completed | Phase 3 | A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer | November 15, 2013 | March 27, 2018 |
| NCT01959490 | Completed | Phase 2 | Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer | September 24, 2013 | March 29, 2017 |
| NCT01964391 | Completed | Phase 3 | A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer | February 21, 2014 | November 25, 2018 |
| NCT03003520 | Completed | Phase 2 | A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma | February 28, 2017 | April 24, 2022 |
| NCT01966471 | Completed | Phase 3 | A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer | January 31, 2014 | June 4, 2021 |
| NCT01970540 | Completed | Phase 1 | Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors | May 25, 2011 | August 9, 2017 |
| NCT01974440 | Completed | Phase 3 | A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma | January 31, 2014 | June 21, 2023 |
| NCT01992653 | Completed | Phase 1/Phase 2 | A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma | November 29, 2013 | December 19, 2018 |
| NCT01998906 | Completed | Phase 3 | A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer | May 2002 | July 2012 |
| NCT02032277 | Completed | Phase 3 | A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer | April 2, 2014 | November 12, 2020 |
| NCT03000036 | Completed | N/A | Doxorubicin-associated Cardiac Remodeling Followed by CMR in Breast Cancer Patients | July 2012 | July 2016 |
| NCT02055820 | Completed | Phase 1/Phase 2 | A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL | November 17, 2013 | June 28, 2019 |
| NCT02076620 | Completed | Phase 1 | L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours | January 16, 2013 | January 25, 2018 |
| NCT02997358 | Completed | Phase 3 | Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma | January 18, 2017 | July 28, 2021 |
| NCT02131480 | Completed | Phase 2 | Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma | June 2010 | October 2016 |
| NCT02132949 | Completed | Phase 2 | A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer | July 14, 2014 | August 25, 2020 |
| NCT02177695 | Completed | Phase 2 | S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer | August 28, 2014 | December 1, 2022 |
| NCT02181738 | Completed | Phase 2 | Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) | August 12, 2014 | December 27, 2022 |
| NCT02978495 | Completed | Phase 2 | Neoadjuvant Carboplatin in Triple Negative Breast Cancer | May 17, 2017 | October 22, 2021 |
| NCT02228772 | Completed | Phase 1 | Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults | December 2014 | November 2019 |
| NCT02229084 | Completed | Phase 1/Phase 2 | Vaccination of High Risk Breast Cancer Patients | January 14, 2015 | January 3, 2023 |
| NCT02285062 | Completed | Phase 3 | Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma | February 17, 2015 | July 28, 2022 |
| NCT02292979 | Completed | Phase 2 | Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma. | March 2015 | June 2, 2022 |
| NCT02326025 | Completed | Phase 1 | A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma | January 22, 2015 | November 2, 2018 |
| NCT02348216 | Completed | Phase 1/Phase 2 | Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma | April 21, 2015 | July 27, 2023 |
| NCT02861222 | Completed | Phase 1 | Myocet® in Children With Relapsed or Refractory Non-brainstem Malignant Glioma | October 2010 | April 2013 |
| NCT02377752 | Completed | Phase 1 | A Study of Olaratumab in Japanese Participants With Advanced Cancer | March 23, 2015 | January 14, 2020 |
| NCT02786719 | Completed | N/A | High-Risk Neuroblastoma Chemotherapy Without G-CSF | June 2016 | February 5, 2019 |
| NCT02398240 | Completed | Phase 2 | Brentuximab for Newly Diagnosed Hodgkin Disease | May 2015 | December 2022 |
| NCT02406092 | Completed | Phase 3 | Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A | October 13, 2015 | June 30, 2021 |
| NCT02412670 | Completed | Phase 2 | Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer | August 27, 2015 | May 10, 2022 |
| NCT02413320 | Completed | Phase 2 | Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer | July 2015 | February 1, 2020 |
| NCT02414568 | Completed | Phase 2 | Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin | July 17, 2015 | November 10, 2020 |
| NCT02783599 | Completed | Phase 1 | A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma | October 11, 2016 | July 5, 2018 |
| NCT02419742 | Completed | Phase 4 | Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen | August 18, 2015 | June 24, 2021 |
| NCT02448537 | Completed | Phase 2 | A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas | August 2015 | April 1, 2019 |
| NCT02677116 | Completed | Phase 1 | A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer | August 29, 2016 | April 3, 2019 |
| NCT02670616 | Completed | Phase 2 | Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma | May 1, 2016 | October 2020 |
| NCT01358071 | Completed | Phase 2 | Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer | June 2011 | December 2016 |
| NCT00001498 | Completed | Phase 2 | A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer | February 1996 | December 2000 |
| NCT00002707 | Completed | Phase 3 | Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed | December 1995 | February 2010 |
| NCT00003389 | Completed | Phase 3 | Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma | June 17, 1999 | May 2016 |
| NCT00003782 | Completed | Phase 3 | Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes | March 1999 | December 2012 |
| NCT00003907 | Completed | Phase 2 | Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver | December 15, 1999 | August 2012 |
| NCT00005800 | Completed | Phase 2 | Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer | April 1999 | May 2012 |
| NCT00016406 | Completed | Phase 3 | S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer | May 2001 | February 2012 |
| NCT00001300 | Completed | Phase 3 | A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma | June 1992 | March 2001 |
| NCT00021255 | Completed | Phase 3 | Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer | April 2001 | December 2014 |
| NCT00026208 | Completed | Phase 2 | Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma | June 2001 | February 13, 2017 |
| NCT06313047 | Completed | Pharmacogenetic of Doxorubicin in HCC. | January 1, 2021 | December 30, 2023 | |
| NCT00038610 | Completed | Phase 2 | Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia | March 2001 | July 2014 |
| NCT00041132 | Completed | Phase 2 | S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma | September 2002 | June 2011 |
| NCT00051311 | Completed | Phase 2 | Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers | January 3, 2003 | September 25, 2014 |
| NCT00054665 | Completed | Phase 2 | PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma | February 2003 | July 2009 |
| NCT00068393 | Completed | Phase 2 | Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma | February 24, 2004 | May 2011 |
| NCT00083226 | Completed | Phase 2 | Doxorubicin and Bortezomib in Treating Patients With Liver Cancer | March 2004 | August 2012 |
| NCT00083551 | Completed | Phase 3 | UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy | August 1998 | August 2014 |
| NCT00093795 | Completed | Phase 3 | Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer | October 2004 | June 2016 |
| NCT00094497 | Completed | Phase 3 | Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) | June 2004 | December 2010 |
| NCT00101101 | Completed | Phase 2 | Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma | July 2004 | June 14, 2021 |
| NCT00102219 | Completed | Phase 2 | A Study of Pemetrexed Plus Doxorubicin Given to Patients With Advanced Breast Cancer | October 2004 | October 2007 |
| NCT00102609 | Completed | Phase 1 | A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma | April 2005 | October 2007 |
| NCT00109837 | Completed | Phase 2 | S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | April 2005 | November 2014 |
| NCT00115414 | Completed | Phase 2 | Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC) | ||
| NCT00118209 | Completed | Phase 3 | Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma | May 2005 | November 15, 2021 |
| NCT00121992 | Completed | Phase 3 | Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment | July 1999 | March 6, 2013 |
| NCT00123929 | Completed | Phase 2 | Genetic Expression and Prediction of Response to Neoadjuvant Docetaxel or Doxorubicin in Locally Advanced Breast Cancer | January 2005 | May 2009 |
| NCT05291338 | Completed | Pharmacogenetic Study in Hepatocellular Carcinoma Patients. | January 1, 2022 | April 1, 2023 | |
| NCT00129376 | Completed | Phase 2 | Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as Neoadjuvant Treatment of Breast Cancer Patients | February 2003 | February 2010 |
| NCT00129389 | Completed | Phase 3 | FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients | September 19, 2003 | October 1, 2013 |
| NCT00131963 | Completed | A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide ©) and/or Weekly Paclitaxel | October 2003 | October 2014 | |
| NCT00136565 | Completed | Phase 2 | Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma | January 8, 2006 | April 18, 2011 |
| NCT00140595 | Completed | Phase 3 | ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1 | December 2003 | January 2009 |
| NCT00144807 | Completed | Phase 2 | ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma | December 2003 | April 2012 |
| NCT00146562 | Completed | Phase 2 | Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer | July 2003 | May 2007 |
| NCT00148681 | Completed | Phase 2 | Preoperative Herceptin and Navelbine for Breast Cancer | May 2001 | May 2003 |
| NCT00149214 | Completed | Phase 2 | Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens | September 2005 | March 2011 |
| NCT00165178 | Completed | Phase 3 | Treatment of Acute Lymphoblastic Leukemia in Children | September 2000 | May 2011 |
| NCT00165191 | Completed | Phase 2 | Doxorubicin, Cisplatin, 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus | August 1998 | January 2006 |
| NCT00169130 | Completed | Phase 2/Phase 3 | ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma | October 1999 | |
| NCT05112536 | Completed | Phase 2 | Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer | March 3, 2022 | March 13, 2023 |
| NCT00191789 | Completed | Phase 2 | Neoadjuvant Sequential Administration of Two Gemcitabine Combinations in Operable Breast Cancer | February 2003 | April 2009 |
| NCT00193115 | Completed | Phase 2 | Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer | March 2004 | January 2009 |
| NCT00194753 | Completed | Phase 2 | Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks; Wkly Taxol x 12 | December 2001 | March 2011 |
| NCT00201708 | Completed | Phase 2 | Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide in Axillary Node-Positive Breast Cancer | October 2004 | February 2014 |
| NCT00206518 | Completed | Phase 2 | Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients | September 2004 | October 10, 2016 |
| NCT00211185 | Completed | Phase 2 | A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma | March 14, 2004 | December 23, 2009 |
| NCT00217425 | Completed | Phase 2 | Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms | September 14, 2006 | March 2014 |
| NCT04933617 | Completed | Phase 1 | Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas | March 24, 2022 | November 30, 2023 |
| NCT00254592 | Completed | Phase 2 | Neoadjuvant Treatment of Breast Cancer | October 2005 | September 4, 2013 |
| NCT00256243 | Completed | Phase 2 | Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer | April 2004 | July 2012 |
| NCT00262990 | Completed | Phase 3 | Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer | November 2005 | |
| NCT00278109 | Completed | Phase 1/Phase 2 | Partial Breast Irradiation With Chemotherapy | July 2004 | December 2016 |
| NCT00288431 | Completed | Phase 1 | Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015) | February 2006 | July 2008 |
| NCT00290498 | Completed | Phase 2 | Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger | August 1, 2005 | August 11, 2017 |
| NCT00299182 | Completed | Phase 1/Phase 2 | Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma | March 2006 | April 2012 |
| NCT00305084 | Completed | Phase 1 | Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors | February 28, 2006 | May 8, 2007 |
| NCT00314977 | Completed | Phase 3 | Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable or Locally Advanced Breast Cancer. | February 2006 | |
| NCT00336791 | Completed | Phase 3 | Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer | September 2003 | September 2010 |
| NCT04790903 | Completed | Phase 1 | A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL) | July 2, 2021 | May 21, 2024 |
| NCT00365417 | Completed | Phase 2 | Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer | August 2006 | November 2009 |
| NCT00369681 | Completed | Phase 2 | Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma | May 2006 | October 2014 |
| NCT00379574 | Completed | Phase 1/Phase 2 | Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL | September 2006 | January 2011 |
| NCT00390793 | Completed | Phase 2 | Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. | September 28, 2006 | February 2, 2024 |
| NCT00404066 | Completed | Phase 2 | Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer | October 2006 | March 2011 |
| NCT04660799 | Completed | Phase 2 | A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL) | February 24, 2021 | October 11, 2022 |
| NCT00440726 | Completed | Phase 1/Phase 2 | Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL) | August 4, 2006 | February 26, 2011 |
| NCT00446030 | Completed | Phase 2 | Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer | March 2007 | August 2010 |
| NCT04584112 | Completed | Phase 1 | A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer | September 28, 2020 | March 8, 2023 |
| NCT00450801 | Completed | Phase 2 | R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma | April 2004 | July 2015 |
| NCT00451178 | Completed | Phase 2 | A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only | May 2007 | January 2013 |
| NCT00455533 | Completed | Phase 2 | Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer | October 2007 | December 2009 |
| NCT00470301 | Completed | Phase 1/Phase 2 | Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer | April 2007 | September 2013 |
| NCT02529852 | Completed | Phase 1/Phase 2 | A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma | November 4, 2015 | October 31, 2022 |
| NCT02617485 | Completed | Phase 3 | MabionCD20 Compared to MabThera in Lymphoma Patients | December 2015 | January 2018 |
| NCT02483247 | Completed | Phase 1 | A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer | September 2015 | May 2019 |
| NCT02605915 | Completed | Phase 1 | Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer | December 31, 2015 | November 13, 2019 |
| NCT02596971 | Completed | Phase 1/Phase 2 | A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) | December 22, 2015 | May 8, 2020 |
| NCT06201507 | Enrolling by invitation | Phase 2 | BV-AVD-R Treatment Children Hodgkin's Lymphoma | October 1, 2022 | December 31, 2025 |
| NCT06441097 | Not yet recruiting | Phase 2 | Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL | December 31, 2024 | December 31, 2027 |
| NCT03892330 | Not yet recruiting | Phase 4 | Combination Therapy of Anthracyclines for Children With Nephroblastoma | June 1, 2019 | June 30, 2045 |
| NCT04199026 | Not yet recruiting | Early Phase 1 | Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma | January 31, 2025 | December 31, 2025 |
| NCT05006664 | Not yet recruiting | Phase 2 | Brentuximab Vedotin in Combination With CHEP in Patient With PTCL | October 2021 | October 2024 |
| NCT05287308 | Not yet recruiting | N/A | Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study | March 2022 | September 2027 |
| NCT05872412 | Not yet recruiting | Phase 2 | Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer | June 1, 2023 | April 30, 2024 |
| NCT06023862 | Not yet recruiting | Phase 2 | A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) | January 22, 2024 | December 31, 2029 |
| NCT06124157 | Not yet recruiting | Phase 3 | A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL) | July 22, 2024 | December 1, 2030 |
| NCT06220032 | Not yet recruiting | Phase 3 | Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma | May 21, 2024 | December 15, 2028 |
| NCT06249191 | Not yet recruiting | Phase 1/Phase 2 | Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma | May 31, 2024 | April 1, 2027 |
| NCT06277154 | Not yet recruiting | Phase 2 | MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | February 2024 | February 2027 |
| NCT06295094 | Not yet recruiting | Phase 2 | The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients. | September 2024 | January 2028 |
| NCT06313996 | Not yet recruiting | Phase 3 | A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma | March 29, 2024 | October 16, 2031 |
| NCT06317662 | Not yet recruiting | Phase 2 | Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia | July 31, 2024 | December 21, 2027 |
| NCT06340568 | Not yet recruiting | Phase 3 | A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer | August 2024 | December 2028 |
| NCT06394492 | Not yet recruiting | Phase 3 | SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer | May 31, 2024 | December 31, 2026 |
| NCT06401330 | Not yet recruiting | Phase 3 | A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) | June 12, 2024 | February 13, 2031 |
| NCT06404463 | Not yet recruiting | Phase 2 | QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer | May 6, 2024 | November 6, 2030 |
| NCT06422806 | Not yet recruiting | Phase 2 | Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas | June 14, 2024 | June 30, 2026 |
| NCT06425302 | Not yet recruiting | Phase 2 | A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma | August 3, 2024 | November 27, 2028 |
| NCT05389423 | Recruiting | Phase 1 | Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas | June 27, 2023 | June 1, 2032 |
| NCT05371093 | Recruiting | Phase 3 | Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma | September 12, 2022 | October 2030 |
| NCT05959720 | Recruiting | Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil | September 5, 2023 | June 2030 | |
| NCT02797717 | Recruiting | N/A | Treatment for Classical Hodgkin Lymphoma in Children and Adolescents | November 2015 | December 2027 |
| NCT06239272 | Recruiting | Phase 1/Phase 2 | NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) | March 27, 2024 | June 2037 |
| NCT04139304 | Recruiting | Early Phase 1 | A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma | May 24, 2021 | August 2027 |
| NCT05351346 | Recruiting | Phase 3 | Genotype-guided Treatment in DLBCL | June 1, 2022 | June 1, 2026 |
| NCT06251180 | Recruiting | Phase 1 | Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma | April 10, 2024 | December 31, 2029 |
| NCT04203641 | Recruiting | Phase 1/Phase 2 | L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer | December 11, 2019 | August 31, 2025 |
| NCT04213794 | Recruiting | Early Phase 1 | Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients | November 8, 2019 | January 30, 2025 |
| NCT04216524 | Recruiting | Phase 2 | Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm | May 29, 2020 | December 31, 2026 |
| NCT04221035 | Recruiting | Phase 3 | High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) | November 5, 2019 | November 2032 |
| NCT01704716 | Recruiting | Phase 3 | High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN) | February 2002 | September 2026 |
| NCT05404945 | Recruiting | Phase 2 | Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above | July 26, 2022 | October 3, 2027 |
| NCT04043494 | Recruiting | Phase 3 | International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma | August 23, 2019 | November 22, 2027 |
| NCT04243616 | Recruiting | Phase 2 | Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer | March 5, 2020 | January 1, 2026 |
| NCT02811523 | Recruiting | Phase 1 | In Vivo Lung Perfusion for Pulmonary Metastases of Sarcoma | February 2016 | February 2025 |
| NCT04322318 | Recruiting | Phase 2 | A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT | October 19, 2020 | July 1, 2027 |
| NCT04329494 | Recruiting | Phase 1 | PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer | August 21, 2020 | December 30, 2025 |
| NCT04383743 | Recruiting | Phase 2 | Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer | November 24, 2020 | October 28, 2025 |
| NCT04423926 | Recruiting | Phase 1/Phase 2 | Lenalidomide in Combination With CHOP in Patients With Untreated PTCL | June 10, 2020 | December 31, 2024 |
| NCT04432714 | Recruiting | Phase 1/Phase 2 | Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement | June 9, 2020 | December 31, 2026 |
| NCT04443348 | Recruiting | Phase 2 | Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) | December 16, 2020 | December 2024 |
| NCT05303792 | Recruiting | Phase 2 | Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma | February 27, 2023 | May 2028 |
| NCT05292664 | Recruiting | Phase 1 | Venetoclax Basket Trial for High Risk Hematologic Malignancies | March 29, 2023 | April 2, 2027 |
| NCT06377566 | Recruiting | Phase 2 | A Study of BV-AVD in People With Bulky Hodgkin Lymphoma | April 17, 2024 | April 2027 |
| NCT04535713 | Recruiting | Phase 2 | GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma | September 30, 2020 | December 31, 2025 |
| NCT05929768 | Recruiting | Phase 3 | Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | September 15, 2023 | April 2033 |
| NCT03277924 | Recruiting | Phase 1/Phase 2 | Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas | May 31, 2017 | June 30, 2025 |
| NCT04594798 | Recruiting | Phase 2 | A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL | September 20, 2021 | July 31, 2024 |
| NCT04625907 | Recruiting | Phase 1/Phase 2 | FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma | September 17, 2020 | June 2030 |
| NCT04638790 | Recruiting | Phase 3 | First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1) | February 1, 2020 | December 31, 2026 |
| NCT06284122 | Recruiting | Phase 3 | Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 | May 2024 | April 2034 |
| NCT04650984 | Recruiting | Phase 3 | A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma | November 29, 2017 | December 31, 2025 |
| NCT05270057 | Recruiting | Phase 1 | Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies | January 26, 2023 | May 2026 |
| NCT06191744 | Recruiting | Phase 3 | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma | February 5, 2024 | May 18, 2037 |
| NCT04685616 | Recruiting | Phase 3 | Brentuximab Vedotin in Early Stage Hodgkin Lymphoma | April 14, 2022 | September 2032 |
| NCT04745949 | Recruiting | Phase 2 | PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy | May 10, 2021 | August 3, 2025 |
| NCT04757337 | Recruiting | Phase 3 | Comparison of Oral Cyclophosphamide vs Doxorubicin in ≥65 Years Old Advanced or Metastatic Soft Tissue Sarcoma Patients | June 18, 2021 | April 2026 |
| NCT05200312 | Recruiting | Phase 2 | A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma | February 1, 2022 | February 1, 2025 |
| NCT04776525 | Recruiting | Phase 2 | Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma | April 27, 2021 | September 2036 |
| NCT05899621 | Recruiting | A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL | June 1, 2023 | June 30, 2027 | |
| NCT05848765 | Recruiting | Phase 2 | Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy | September 4, 2023 | November 30, 2031 |
| NCT04803201 | Recruiting | Phase 2 | Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma | July 30, 2021 | January 1, 2026 |
| NCT05099666 | Recruiting | Phase 1/Phase 2 | Lurbinectedin + Doxorubicin In Leiomyosarcoma | February 4, 2022 | July 2025 |
| NCT04835870 | Recruiting | Phase 2 | Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL | April 1, 2021 | October 1, 2025 |
| NCT04847063 | Recruiting | Phase 1 | Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies | October 19, 2021 | December 30, 2031 |
| NCT05088057 | Recruiting | Phase 2 | Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer | September 20, 2021 | November 1, 2024 |
| NCT04874311 | Recruiting | Phase 2 | Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma | March 1, 2022 | March 2025 |
| NCT04884035 | Recruiting | Phase 1 | Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma | September 15, 2021 | February 4, 2026 |
| NCT05809830 | Recruiting | Phase 1/Phase 2 | Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas | May 29, 2023 | May 8, 2026 |
| NCT04922567 | Recruiting | Phase 2 | Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | April 1, 2021 | December 31, 2026 |
| NCT06172296 | Recruiting | Phase 3 | Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma | April 19, 2024 | December 31, 2029 |
| NCT04947501 | Recruiting | Early Phase 1 | A Study of N9 Chemotherapy in Children With Neuroblastoma | June 22, 2021 | June 22, 2025 |
| NCT04968106 | Recruiting | Phase 2 | Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO) | December 7, 2022 | October 2027 |
| NCT05020860 | Recruiting | Phase 2 | Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer | April 18, 2023 | November 2029 |
| NCT06336395 | Recruiting | Phase 2 | Ma-Spore ALL 2020 Study | March 4, 2020 | March 2030 |
| NCT05774275 | Recruiting | Phase 1/Phase 2 | The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma | August 25, 2022 | August 24, 2029 |
| NCT04996160 | Recruiting | Phase 1 | Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2) | July 9, 2021 | December 2025 |
| NCT02449265 | Recruiting | Phase 3 | Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma | October 2015 | October 2025 |
| NCT03360760 | Recruiting | N/A | Timing of Surgery in Nonmetastatic Osteosarcoma of the Pelvis and Sacrum | August 1, 2018 | February 2025 |
| NCT05766605 | Recruiting | Phase 3 | Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial | January 1, 2023 | January 30, 2026 |
| NCT02853500 | Recruiting | N/A | Effect of Surefire Infusion Device on Tumor Response to Regional Intra-arterial Therapy for Primary Liver Malignancies | July 2016 | July 2027 |
| NCT03412643 | Recruiting | Phase 2 | Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling | May 14, 2018 | October 30, 2023 |
| NCT03420014 | Recruiting | Phase 2 | Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA) | December 27, 2018 | December 2025 |
| NCT05701436 | Recruiting | Phase 3 | Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial | September 1, 2022 | March 1, 2026 |
| NCT06164275 | Recruiting | Phase 2 | Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma | February 6, 2024 | December 31, 2031 |
| NCT06155331 | Recruiting | Phase 4 | Evaluation of Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients | December 2023 | December 2025 |
| NCT05673785 | Recruiting | Phase 2 | A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL) | February 10, 2023 | December 31, 2027 |
| NCT06132958 | Recruiting | Phase 3 | Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) | December 6, 2023 | January 10, 2028 |
| NCT05661201 | Recruiting | Phase 1 | NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors | April 12, 2023 | January 2026 |
| NCT06356129 | Recruiting | Phase 3 | Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma | June 24, 2024 | November 20, 2029 |
| NCT02449252 | Recruiting | Phase 3 | Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Follicular Lymphoma | October 2015 | October 2025 |
| NCT05645380 | Recruiting | Phase 2 | Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC | December 5, 2022 | December 2025 |
| NCT05630209 | Recruiting | Phase 1/Phase 2 | Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG | January 4, 2023 | January 2026 |
| NCT03571321 | Recruiting | Phase 1 | Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia | May 28, 2019 | September 5, 2027 |
| NCT06121570 | Recruiting | Phase 1 | Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer | November 1, 2023 | August 31, 2031 |
| NCT03007147 | Recruiting | Phase 3 | Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | August 8, 2017 | September 30, 2027 |
| NCT05615623 | Recruiting | Phase 1/Phase 2 | Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG | January 4, 2023 | July 4, 2025 |
| NCT05605899 | Recruiting | Phase 3 | Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma | February 10, 2023 | March 2031 |
| NCT03643276 | Recruiting | Phase 3 | Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 | July 15, 2018 | July 14, 2028 |
| NCT02449278 | Recruiting | Phase 3 | The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma | October 2015 | October 2025 |
| NCT06112379 | Recruiting | Phase 3 | A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer | November 14, 2023 | August 28, 2030 |
| NCT06097364 | Recruiting | Phase 3 | A Study to Learn How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Compared to Rituximab and Chemotherapy in Adult Participants With Previously Untreated Follicular Lymphoma | November 14, 2023 | January 24, 2030 |
| NCT02372409 | Recruiting | Phase 2 | Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors | August 14, 2015 | August 31, 2030 |
| NCT03719105 | Recruiting | Early Phase 1 | Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma | March 1, 2019 | December 31, 2026 |
| NCT05600686 | Recruiting | Phase 2 | Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma | May 24, 2023 | February 1, 2028 |
| NCT05580887 | Recruiting | Intestinal Microbiota Impact for Prognosis and Treatment Outcomes in Early Luminal Breast Cancer and Pancreatic Cancer Patients | May 12, 2022 | August 2025 | |
| NCT05578976 | Recruiting | Phase 3 | A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | February 8, 2023 | December 30, 2029 |
| NCT03755804 | Recruiting | Phase 2 | Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 | December 12, 2018 | July 1, 2028 |
| NCT03758989 | Recruiting | Phase 2 | A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma | May 8, 2019 | June 1, 2026 |
| NCT03033914 | Recruiting | Phase 1/Phase 2 | A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) | January 25, 2017 | January 2026 |
| NCT06091865 | Recruiting | Phase 3 | A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma | December 13, 2023 | September 18, 2028 |
| NCT06091254 | Recruiting | Phase 3 | A Trial to Learn if Odronextamab is Safe and Well-tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma | December 12, 2023 | April 3, 2029 |
| NCT06318897 | Recruiting | Phase 2 | Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer | May 29, 2024 | September 30, 2027 |
| NCT03805022 | Recruiting | Phase 3 | Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas | February 14, 2019 | February 2025 |
| NCT06088290 | Recruiting | Phase 2/Phase 3 | Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma | September 21, 2023 | November 26, 2026 |
| NCT05467670 | Recruiting | Phase 2 | Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer | December 16, 2022 | December 2027 |
| NCT03837873 | Recruiting | Phase 2 | DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma | January 21, 2019 | September 1, 2024 |
| NCT05455697 | Recruiting | Phase 1/Phase 2 | Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma | January 26, 2023 | July 6, 2026 |
| NCT06245889 | Recruiting | Phase 2 | PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC | May 1, 2024 | June 2030 |
| NCT06058377 | Recruiting | Phase 3 | Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | November 27, 2023 | May 31, 2026 |
| NCT06047080 | Recruiting | Phase 3 | An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma | September 18, 2023 | February 28, 2029 |
| NCT06250959 | Recruiting | Phase 2 | RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL. | February 5, 2024 | December 31, 2026 |
| NCT03899337 | Recruiting | Phase 2 | A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome | July 23, 2019 | May 31, 2027 |
| NCT05981014 | Recruiting | Phase 1/Phase 2 | Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer | August 1, 2023 | May 31, 2035 |
| NCT03943901 | Recruiting | Phase 2 | Split-Dose R-CHOP for Older Adults With DLBCL | February 17, 2021 | May 2026 |
| NCT05453500 | Recruiting | Phase 2 | Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia | March 27, 2023 | September 1, 2030 |
| NCT05422066 | Recruiting | Phase 2 | Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma | July 26, 2022 | December 31, 2025 |
| NCT05406401 | Recruiting | Phase 2 | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007) | July 14, 2022 | January 26, 2026 |
| NCT04231877 | Suspended | Phase 1 | Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma | October 27, 2020 | December 1, 2031 |
| NCT03145558 | Suspended | Phase 2 | TATE Versus TACE in Intermediate Stage HCC | December 5, 2017 | December 31, 2024 |
| NCT03150693 | Suspended | Phase 3 | Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia | June 1, 2017 | August 2025 |
| NCT02758366 | Terminated | Phase 2 | Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma | February 2016 | January 16, 2020 |
| NCT02419469 | Terminated | Phase 2 | Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | November 13, 2015 | June 22, 2017 |
| NCT02379585 | Terminated | Phase 1/Phase 2 | Fasting on Newly Diagnosed Breast Cancer | January 2013 | August 2015 |
| NCT02855359 | Terminated | Phase 2 | Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma | August 2016 | May 15, 2018 |
| NCT02359162 | Terminated | Phase 3 | Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage | May 2015 | June 2017 |
| NCT02261805 | Terminated | Phase 1/Phase 2 | A Phase I/II Study of Ganetespib in Combination With Doxorubicin | October 2014 | October 2016 |
| NCT02255110 | Terminated | Phase 2 | A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma | December 10, 2014 | January 12, 2016 |
| NCT02958163 | Terminated | Phase 2 | Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR) | February 20, 2017 | October 17, 2017 |
| NCT01964755 | Terminated | Phase 2 | Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma | April 21, 2009 | June 7, 2018 |
| NCT01925612 | Terminated | Phase 2 | Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) | August 2013 | May 1, 2017 |
| NCT01887587 | Terminated | Phase 1 | Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia | June 2013 | February 29, 2016 |
| NCT01779050 | Terminated | Phase 2 | Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells | December 19, 2013 | September 1, 2021 |
| NCT01746173 | Terminated | Phase 2 | CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma | July 2013 | October 2014 |
| NCT01659554 | Terminated | Phase 2 | A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers | March 2012 | April 2014 |
| NCT03225924 | Terminated | Phase 1/Phase 2 | Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy | July 26, 2017 | October 18, 2019 |
| NCT01659099 | Terminated | Phase 3 | GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma | September 2012 | December 31, 2017 |
| NCT01548573 | Terminated | Phase 2 | Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment | May 2012 | August 2014 |
| NCT01498588 | Terminated | Phase 2 | Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer | November 2011 | June 2015 |
| NCT03329378 | Terminated | Phase 2 | Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer | January 24, 2019 | March 7, 2021 |
| NCT01390584 | Terminated | Phase 2 | Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma | May 24, 2013 | May 18, 2018 |
| NCT01321008 | Terminated | Phase 1/Phase 2 | Stage I/II Nasal NK Cell Lymphoma | May 2011 | May 2013 |
| NCT01313884 | Terminated | Phase 2 | Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma | May 2011 | July 2014 |
| NCT01287741 | Terminated | Phase 3 | A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA) | July 26, 2011 | January 31, 2018 |
| NCT03515200 | Terminated | Phase 1 | Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia | April 20, 2018 | July 29, 2020 |
| NCT01258634 | Terminated | Phase 1 | A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response | July 2010 | November 2011 |
| NCT01220128 | Terminated | Phase 2 | Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer | April 11, 2011 | November 14, 2014 |
| NCT01186328 | Terminated | Phase 1 | EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) | August 24, 2010 | January 10, 2012 |
| NCT01177683 | Terminated | Phase 1/Phase 2 | Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma | July 2010 | December 2017 |
| NCT01104298 | Terminated | Phase 2 | Doxorubicin vs. Trabectedin Plus Doxorubicin in Non Operable and/or Metastatic STS | November 2009 | May 2014 |
| NCT01090128 | Terminated | Phase 1 | Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer | September 2008 | March 24, 2017 |
| NCT03698227 | Terminated | Phase 2 | OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients | November 12, 2018 | June 25, 2020 |
| NCT01014767 | Terminated | Phase 3 | Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors | November 2009 | January 2014 |
| NCT00960063 | Terminated | Phase 1 | A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006) | November 11, 2009 | December 22, 2010 |
| NCT00928200 | Terminated | Phase 1 | Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224) | April 13, 2009 | June 4, 2010 |
| NCT00883116 | Terminated | Phase 3 | A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer | August 2009 | February 2014 |
| NCT00859495 | Terminated | Phase 2 | Trimodal Lung-Sparing Treatment of Pleural Mesothelioma | February 2008 | February 2012 |
| NCT00841945 | Terminated | Phase 3 | Treatment of Aggressive Localized Lymphoma | April 2005 | February 2017 |
| NCT03860844 | Terminated | Phase 2 | Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | August 6, 2019 | May 26, 2023 |
| NCT03864419 | Terminated | Phase 1 | Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda | October 24, 2019 | July 26, 2023 |
| NCT03878524 | Terminated | Phase 1 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | April 1, 2020 | December 10, 2020 |
| NCT03912818 | Terminated | Phase 2 | Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer | April 10, 2019 | August 11, 2022 |
| NCT00809341 | Terminated | Phase 2 | R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma | January 2009 | April 2014 |
| NCT00808899 | Terminated | Phase 2 | Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma | December 2008 | July 2009 |
| NCT00755261 | Terminated | Phase 2 | Phase II Study of Doxorubicin and Avastin® in Sarcoma. | September 2008 | November 2010 |
| NCT00673179 | Terminated | N/A | Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy | May 2008 | November 2010 |
| NCT00635726 | Terminated | Phase 2 | Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer | February 2008 | February 2013 |
| NCT00609765 | Terminated | Phase 2 | Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors | August 2007 | March 2008 |
| NCT00512980 | Terminated | Phase 2 | PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma | August 2008 | |
| NCT00484601 | Terminated | Phase 2 | Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma | April 15, 2004 | November 7, 2007 |
| NCT00461344 | Terminated | Phase 2 | Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer | July 2004 | August 2007 |
| NCT00450385 | Terminated | Phase 2 | Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP) | April 24, 2007 | May 2016 |
| NCT00439296 | Terminated | Phase 1/Phase 2 | ABT-751 With Chemotherapy for Relapsed Pediatric ALL | May 22, 2006 | September 23, 2009 |
| NCT04780464 | Terminated | Phase 3 | A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma | April 11, 2022 | November 11, 2023 |
| NCT00361621 | Terminated | Phase 2 | Ph II CHOP+Velcade in Mediastinal LBCL | July 2006 | May 2008 |
| NCT00235235 | Terminated | A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer | September 2005 | December 2010 | |
| NCT00225173 | Terminated | Phase 2 | Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease | October 2001 | September 2006 |
| NCT04996004 | Terminated | Phase 2 | A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma | June 22, 2021 | December 7, 2023 |
| NCT05100628 | Terminated | Phase 1 | A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma | February 11, 2022 | May 26, 2023 |
| NCT00176293 | Terminated | Phase 2 | Randomized Phase II Trial of Doxil With or Without Dexamethasone for Metastatic Hormone Refractory Prostate Cancer | October 2005 | February 2007 |
| NCT00165087 | Terminated | Phase 3 | Treatment of Childhood Acute Lymphoblastic Leukemia | January 1996 | September 2006 |
| NCT00135499 | Terminated | Phase 3 | R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma | October 16, 2001 | April 27, 2010 |
| NCT05207514 | Terminated | Phase 3 | Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer | March 31, 2022 | May 9, 2024 |
| NCT00126191 | Terminated | Phase 2 | Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma | July 2005 | June 2011 |
| NCT00088881 | Terminated | Phase 2 | Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma | December 2004 | March 2011 |
| NCT00074490 | Terminated | Phase 2 | Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers | January 1, 2004 | August 16, 2017 |
| NCT00038142 | Terminated | Phase 2 | Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients | November 1997 | March 2016 |
| NCT00060346 | Terminated | Phase 2 | Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia | October 5, 2004 | August 2012 |
| NCT02560051 | Terminated | Phase 2 | Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer | November 2015 | September 14, 2017 |
| NCT02531308 | Terminated | Phase 2 | Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL) | July 2015 | July 2016 |
| NCT02494713 | Terminated | Phase 2 | Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer | October 2015 | September 14, 2017 |
| NCT02472353 | Terminated | Phase 2 | Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer | July 2014 | May 23, 2018 |
| NCT02626455 | Terminated | Phase 3 | Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) | January 6, 2016 | November 10, 2023 |
| NCT02420717 | Terminated | Phase 2 | Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia | July 15, 2015 | January 20, 2021 |
| NCT02732015 | Terminated | Phase 2 | Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy | October 12, 2016 | July 10, 2020 |
| NCT02419755 | Terminated | Phase 2 | Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies | April 14, 2015 | December 31, 2016 |
| NCT03553537 | Unknown status | Phase 3 | Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | June 2018 | July 2021 |
| NCT04498793 | Unknown status | Phase 2 | Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer | September 2020 | December 2022 |
| NCT04181489 | Unknown status | Phase 2 | Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS | January 1, 2019 | December 30, 2023 |
| NCT00718484 | Unknown status | Phase 2 | A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue Sarcoma | August 2008 | April 2014 |
| NCT01920503 | Unknown status | International Registry on Cholangiocarcinoma Treatment | July 2013 | August 2020 | |
| NCT03018626 | Unknown status | Phase 3 | R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL | July 27, 2017 | January 2021 |
| NCT02078388 | Unknown status | Correlation Between Genetic Variants and Long-term Cardiac Effects Induced by Doxorubicin in Breast Cancer Patients | November 2013 | ||
| NCT02953184 | Unknown status | Phase 2 | Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy | November 2016 | November 2020 |
| NCT02951728 | Unknown status | Phase 1/Phase 2 | Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma | October 2016 | October 2020 |
| NCT02812654 | Unknown status | Phase 2 | Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Sarcoma Treatment | March 2015 | March 2019 |
| NCT02918747 | Unknown status | Phase 2 | PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage | September 2016 | December 2021 |
| NCT02894645 | Unknown status | Phase 4 | Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study | October 2008 | |
| NCT02362165 | Unknown status | Phase 3 | CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma | April 2015 | May 2018 |
| NCT02866370 | Unknown status | Phase 2 | Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium | April 2015 | March 2021 |
| NCT02559154 | Unknown status | Phase 4 | Modified Bortezomib-based Combination Therapy for Multiple Myeloma | July 2010 | December 2018 |
| NCT00209222 | Unknown status | Phase 3 | Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL | July 2004 | December 2014 |
| NCT00209209 | Unknown status | Phase 3 | Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL | January 14, 2004 | December 2018 |
| NCT05049473 | Unknown status | Phase 2 | Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14. | January 2014 | January 2024 |
| NCT00324467 | Unknown status | Phase 2 | Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment | August 2006 | December 2021 |
| NCT02784015 | Unknown status | Phase 2 | Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma | May 2016 | May 2023 |
| NCT02685657 | Unknown status | Phase 2 | Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer | September 2016 | |
| NCT02506777 | Unknown status | Phase 2 | Neoadjuvant FDC With Melatonin or Metformin for Locally Advanced Breast Cancer. | July 2015 | August 2020 |
| NCT02428751 | Unknown status | Phase 3 | R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma | September 2015 | May 2020 |
| NCT02771743 | Unknown status | Phase 2 | Response-based Treatment of High-risk Neuroblastoma | April 2015 | March 2023 |
| NCT00131027 | Unknown status | Phase 3 | High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL) | September 2002 | September 2011 |
| NCT04656262 | Unknown status | Phase 3 | Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients | September 10, 2018 | January 31, 2023 |
| NCT02753647 | Unknown status | Phase 2 | Chidamide Plus R-CHOP in Elderly DLBCL | April 2016 | April 2019 |
| NCT04025593 | Unknown status | Phase 2 | Biomarker Guided Treatment in DLBCL | July 17, 2019 | June 1, 2023 |
| NCT03975205 | Unknown status | Early Phase 1 | To Study the Concentration Level of, Doxil, and Doxorubicin at Various Time Frames | July 1, 2019 | December 31, 2019 |
| NCT03952572 | Unknown status | Phase 3 | Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma | May 10, 2019 | April 30, 2023 |
| NCT02631109 | Unknown status | Phase 3 | L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis | December 2015 | November 2019 |
| NCT03949634 | Unknown status | Phase 3 | Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD) | September 1, 2017 | October 31, 2020 |
| NCT03853044 | Unknown status | Phase 2 | Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma | December 29, 2018 | December 2022 |
| NCT00820690 | Unknown status | Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer | July 2008 | September 2017 | |
| NCT03734068 | Unknown status | Chemoembolization Using LifePearl Polyethylene Glycol Drug Eluting Microspheres With Doxorubicin in HCC | June 13, 2018 | December 2021 | |
| NCT00990860 | Unknown status | Phase 2 | Study in Asia of the Combination of TACE With Sorafenib in HCC Patients | February 2009 | |
| NCT01009970 | Unknown status | Phase 2 | Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma | May 2010 | May 2012 |
| NCT03617432 | Unknown status | Phase 2 | Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients | August 28, 2018 | September 30, 2022 |
| NCT00486668 | Unknown status | Phase 3 | A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer | July 2007 | March 2017 |
| NCT03542669 | Unknown status | Phase 1 | Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer | August 3, 2018 | December 30, 2023 |
| NCT01272557 | Unknown status | Phase 2 | Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial | December 2010 | December 2014 |
| NCT03497702 | Unknown status | Phase 2 | Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer | May 8, 2017 | January 2024 |
| NCT03340376 | Unknown status | Phase 2 | Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer | August 30, 2017 | September 2022 |
| NCT01468740 | Unknown status | Phase 2 | Prospective Study on HIV-related Hodgkin Lymphoma | March 2004 | July 2012 |
| NCT01547741 | Unknown status | Phase 3 | Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer | April 2012 | November 2023 |
| NCT01670500 | Unknown status | Phase 2 | Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa | October 2012 | April 2023 |
| NCT01719835 | Unknown status | Phase 2 | CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study | March 2012 | August 2022 |
| NCT02858804 | Unknown status | Phase 4 | EDOCH Alternating With DHAP for New Diagnosed Younger MCL | January 2016 | June 2020 |
| NCT03108300 | Unknown status | Phase 2 | Use of Propranolol Hydrochloride in the Treatment of Metastatic STS | August 30, 2019 | August 30, 2021 |
| NCT01858207 | Unknown status | Phase 2 | Combine TACE and RFA Versus RFA Monotherapy in Unilobar HCC of 3.1 to 7 cm Patient | January 2012 | December 2014 |
| NCT04038489 | Withdrawn | Phase 2 | COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer | October 18, 2019 | April 30, 2023 |
| NCT00017160 | Withdrawn | Phase 2 | Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcoma | ||
| NCT03285607 | Withdrawn | Phase 1 | MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer | September 30, 2018 | February 28, 2021 |
| NCT02215876 | Withdrawn | Phase 2 | Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer | September 2014 | March 2020 |
| NCT05934097 | Withdrawn | Phase 1 | FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma | December 2022 | May 2039 |
| NCT02228512 | Withdrawn | Phase 1/Phase 2 | Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas | August 15, 2014 | May 5, 2015 |
| NCT04852367 | Withdrawn | Phase 1 | PanDox: Targeted Doxorubicin in Pancreatic Tumours | June 16, 2021 | March 30, 2023 |
| NCT05177796 | Withdrawn | Phase 2 | Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer | March 11, 2022 | July 26, 2023 |
| NCT02637375 | Withdrawn | N/A | A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer | May 2016 | December 2018 |
| NCT03111069 | Withdrawn | Phase 1 | Study of Doxorubicin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Intraoperative Brachytherapy for Unresectable or Refractory Pelvic and Abdominal Rhabdomyosarcoma and Undifferentiated Sarcomas in Children | August 2018 | August 2021 |
| NCT04762901 | Withdrawn | Phase 1 | LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer | April 1, 2021 | January 2026 |
| NCT03059615 | Withdrawn | Phase 2 | A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS | October 25, 2018 | July 26, 2020 |
| NCT01857726 | Withdrawn | N/A | Comparison of TACE Versus TACE/TACI Combination in Advanced Hepatocellular Carcinoma With Portal Vein Invasion | July 2013 | December 2016 |
| NCT01159236 | Withdrawn | N/A | Molecular Triaging of Newly Diagnosed Breast Cancer | September 2010 | |
| NCT06210750 | Withdrawn | Phase 2 | Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) | August 9, 2024 | September 22, 2026 |
| NCT00124956 | Withdrawn | Phase 1/Phase 2 | Doxorubicin Pharmacokinetic (PK) Study | June 2003 | |
| NCT04974996 | Withdrawn | Phase 1 | A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8) | February 1, 2022 | May 5, 2027 |
| NCT03005015 | Withdrawn | Phase 2 | Lenvatinib in Second Line Endometrial Carcinoma | January 2017 | |
| NCT03437070 | Withdrawn | Phase 1 | Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma | June 2019 | June 2023 |
| NCT01327521 | Withdrawn | Phase 3 | Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma | February 2011 | |
| NCT02053597 | Withdrawn | Phase 2 | TRIal evalUating the Menstrual and Ovarian Function of Young Breast Cancer Patients Treated With a cycloPHosphamide-free Regimen | October 2014 | July 2015 |
| NCT01415765 | Withdrawn | Phase 1/Phase 2 | MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma | July 15, 2011 | January 7, 2014 |
| NCT04639843 | Withdrawn | Phase 1 | Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma | November 3, 2022 | November 3, 2022 |